IBT receives additional funding from BioGaia

March 26, 2015

Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520 000 US dollars.

Read the official IBT press release here
Read the official BioGaia press release here

Latest press releases

2024-09-01 19:27 IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.

2024-08-30 18:38 IBT's phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality Regulatory MAR

2024-08-28 08:30 Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024 Regulatory

2024-08-15 16:44 Patent for Infant Bacterial Therapeutics has been approved in the USA Regulatory MAR

2024-07-08 16:40 “The Connection Study” is completed Regulatory MAR

Press releases

Latest press releases